Advances in Dry Eye

This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States.

DED: One of the Most Common Reasons People Seek Eye Care

The Pathogenesis of DED

The Pathogenesis of DED

The Pathogenesis of DED

The Pathogenesis of DED

The Pathogenesis of DED

Etiological Subtypes

Multifactorial DED: Pathology Cycle

CASE: Barbara Initial Presentation

DED and the Asymptomatic Patient

CASE: Barbara Recognizing the Red Flags

Early Diagnosis Is Critical Potential Consequences of Untreated DED

Know the Risk Factors

Know the Risk Factors Systemic Conditions

Signs and Symptoms

Stepwise Approach to Diagnosis

Assessing a Patient for DED

Diagnostic Tests

Diagnostic Tests (cont)

Diagnostic Tests (cont)

Follow-up Diagnostic Testing

CASE: Barbara (cont) Initial Evaluation

CASE: Barbara Next Steps in Evaluation

Patient Education Environmental Modifications

Assessing Comorbidities

Treating DED The Primary Goal Is Improving QOL

Accurate Assessment of Severity Is Challenging

Stepwise Treatment Approach

Stepwise Treatment Approach (cont)

Tailoring Treatment Evaporative Subtype

Tailoring Treatment Topical Anti-inflammatory Agents

Tailoring Treatment (cont) Topical Anti-inflammatory Agents

Tailoring Treatment Sjögren’s Syndrome

CASE: Barbara Follow-up Diagnostic Testing

CASE: Barbara Treatment Considerations

Concluding Remarks

Abbreviations

Abbreviations (cont)